JAMA Psychiatry
October 22, 2025
A. Jelovac, Cathal Mccaffrey, Masashi Terao et al.
13 citations
Key Points Question For inpatients with moderate to severe depression, is repeated intravenous ketamine superior to a psychoactive placebo (midazolam) in reducing depressive symptoms? Findings In this randomized clinical trial, there was no statistically significant difference in the primary outcome, end-of-treatment Montgomery-Åsberg Depression Rating Scale score, between the ketamine and...
The Social Science Review A Multidisciplinary Journal
October 20, 2025
S. Bose, Amjad Ali
Depression is a major cause of disability across the world, and influences not only emotional but also cognitive health. Although medication and psychotherapy are the main approaches in treating depression, the effect of alternative methods such as mindfulness meditation and pranayama (yogic breathing techniques) have shown to be beneficial to reduce depressive symptoms. Mindfulness meditation,...
Psychiatry Investigation
October 15, 2025
Hong-Ci Lin, Chia-Yu Chang, Ching-Huang Lin et al.
1 citation
This case report discusses a 62-year-old male with treatment-resistant bipolar II depression and hypertension. After poor responses to multiple treatments, an add-on esketamine nasal spray (ESK-NS) was introduced in October 2022. Improvement was seen, and the patient's depressive episode was nearly remitted during the maintenance phase. However, recurrence was noted when ESK-NS frequency was...
Journal of Affective Disorders
October 15, 2025
Mary Lou Chatterton, Johana Kevin Perez, Thao Thai et al.
2 citations
Ketamine is effective for treatment resistant depression (TRD); but cost-effectiveness evidence remains limited. To evaluate the cost-effectiveness of subcutaneous ketamine for TRD from health sector and societal perspectives. A cost-utility analysis alongside the KADS randomised controlled trial (RCT) involved 174 participants receiving ketamine or midazolam (active control) twice weekly for 4...
Frontiers in Psychology
October 14, 2025
Danhong Zhu, Yufeng Yang, Jing Wen et al.
ObjectiveDepression, a prevalent mental health disorder among global youth, adversely impacts educational attainment, social functioning, and psychological wellbeing. Given the established protective function of perceived social support against depressive symptoms, this study investigates how trait mindfulness enhances such support through three mediating factors: therapeutic alliance...
Neuroscience & Biobehavioral Reviews
October 10, 2025
Amel Bouloufa, Sarah Delcourte, Thomas Delannay et al.
3 citations
Major depressive disorder (MDD) is one of the most prevalent psychiatric conditions worldwide, affecting over 350 million people. Standard treatments, primarily antidepressants targeting serotonin, noradrenaline, and/or dopamine, are based on the monoamine hypothesis, which links depression to imbalances in these neurotransmitters. A sizable fraction of patients, however, does not get enough...
The Brown University Psychopharmacology Update
October 10, 2025
A meta‐analysis comprising 17 randomized trials has found that rates of control group improvement in depression studies were lower in psilocybin trials than in studies of esketamine or a selective serotonin reuptake inhibitor (SSRI). The results suggest that psilocybin's overall efficacy in the treatment of depression might be overestimated.
Research in Health and Medicine
October 8, 2025
Aleeyah Uddeen, Janet Lopez, Renata Komalasari et al.
1 citation
Introduction: Mindfulness, through mind-body practices, promotes awareness and presence. Its practice, along with reduced depression, may improve balance and lower fall risk in older adults. This study examined the association between mindfulness, depression, and fall risk among low-income, community-dwelling older adults. Methods: A descriptive cross-sectional study was conducted with 103...
Psychedelic Medicine
October 8, 2025
Elise C. Tarbi, Skye A. Miner, Kabir Nigam et al.
1 citation
Background: Cancer poses an existential threat for patients and caregivers. Psilocybin-assisted therapy (PAT) has emerged as a potential tool to meet these existential needs, yet little is known about how patients describe this element of their cancer journey, and how it might be affected by PAT, especially in the group therapy context. Purpose: To explore how patients with cancer and...
Journal of The American Geriatrics Society
October 6, 2025
Edgar Vásquez-Carrasco, B. H. Branco, Jordan Hernandez-Martinez et al.
This systematic review and meta‐analysis aimed to evaluate the efficacy of mindfulness‐based treatments for older people with mild cognitive impairment (MCI) who also experience depression and cognitive difficulties.